Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition....
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
BMJ Publishing Group
2016-06-01
|
| Colecção: | Journal for ImmunoTherapy of Cancer |
| Acesso em linha: | https://jitc.bmj.com/content/4/1/50.full |
| _version_ | 1831867966534189056 |
|---|---|
| author | Matthias Pauschinger F. Stephen Hodi Patrick A. Ott Thomas F. Gajewski Hussein Tawbi Jason J. Luke Lucie Heinzerling Aliya N. Husain Azadeh Tajmir-Riahi Evan J. Lipson |
| author_facet | Matthias Pauschinger F. Stephen Hodi Patrick A. Ott Thomas F. Gajewski Hussein Tawbi Jason J. Luke Lucie Heinzerling Aliya N. Husain Azadeh Tajmir-Riahi Evan J. Lipson |
| author_sort | Matthias Pauschinger |
| collection | DOAJ |
| description | Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis.Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented.This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety. |
| first_indexed | 2025-03-21T18:47:12Z |
| format | Article |
| id | doaj.art-d608b3db002d4092bb8c767029a98b5d |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2025-03-21T18:47:12Z |
| publishDate | 2016-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-d608b3db002d4092bb8c767029a98b5d2024-06-06T11:25:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262016-06-014110.1186/s40425-016-0152-yCardiotoxicity associated with CTLA4 and PD1 blocking immunotherapyMatthias Pauschinger0F. Stephen Hodi1Patrick A. Ott2Thomas F. Gajewski3Hussein Tawbi4Jason J. Luke5Lucie Heinzerling6Aliya N. Husain7Azadeh Tajmir-Riahi8Evan J. Lipson9Aff5 Paracelsus University Hospital Nuremberg Nürnberg GermanyAff3 grid.65499.370000000121069910Dana Farber Cancer Institute Boston MA USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USAAff3 grid.170205.10000000419367822University of Chicago Comprehensive Cancer Center and Pathology Chicago IL USAAff4 grid.267308.80000000092062401University of Texas MD Anderson Center Houston TX USAAff3 grid.170205.10000000419367822University of Chicago Comprehensive Cancer Center and Pathology Chicago IL USAAff1 grid.411668.c0000000099356525University Hospital Erlangen Erlangen GermanyAff3 grid.170205.10000000419367822University of Chicago Comprehensive Cancer Center and Pathology Chicago IL USAAff1 grid.411668.c0000000099356525University Hospital Erlangen Erlangen GermanyAff6 grid.469474.c0000000086174175Sidney Kimmel Comprehensive Cancer Center Baltimore MD USAImmune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis.Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented.This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.https://jitc.bmj.com/content/4/1/50.full |
| spellingShingle | Matthias Pauschinger F. Stephen Hodi Patrick A. Ott Thomas F. Gajewski Hussein Tawbi Jason J. Luke Lucie Heinzerling Aliya N. Husain Azadeh Tajmir-Riahi Evan J. Lipson Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy Journal for ImmunoTherapy of Cancer |
| title | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy |
| title_full | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy |
| title_fullStr | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy |
| title_full_unstemmed | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy |
| title_short | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy |
| title_sort | cardiotoxicity associated with ctla4 and pd1 blocking immunotherapy |
| url | https://jitc.bmj.com/content/4/1/50.full |
| work_keys_str_mv | AT matthiaspauschinger cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT fstephenhodi cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT patrickaott cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT thomasfgajewski cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT husseintawbi cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT jasonjluke cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT lucieheinzerling cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT aliyanhusain cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT azadehtajmirriahi cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy AT evanjlipson cardiotoxicityassociatedwithctla4andpd1blockingimmunotherapy |